ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 126

Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS

Yann Becker1, Anne-Sophie Julien 2, Alexandra Godbout 3, Éric Boilard 3 and Paul Fortin 4, 1Département de microbiologie et immunologie, Centre de recherche du CHU de Québec - Université Laval, Canada, Quebec, QC, Canada, 2Service de consultation statistique (SCS). Département de mathématiques et de statistique, Québec, QC, Canada, 3Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Québec, Qc, Canada, Québec, QC, Canada, 4Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-mitochondria antibody, antiphospholipid syndrome, auto-immunity and cardiovascular disease, autoantibodies

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Mitochondria are intracellular organelles involved in many biological pathways such as energy supply by oxidative phosphorylation and apoptosis. Mitochondria are considered as derived from the endosymbiosis between an α-proteobacterion and a primitive eukaryotic cell. Mitochondria display molecular features derived from their bacterial origin such as N-formylated peptides or a circular double-stranded DNA with hypomethylated CpG motives. When released onto the extracellular milieu upon tissue damage or cell activation, mitochondria may elicit proinflammatory responses through their recognition by the innate immune system. Little is known about interplays between mitochondria and the adaptive immune system, despite descriptions of humoral responses to mitochondria in some diseases. Our laboratory already reported that anti-mitochondrial antibodies (AMA) targeting whole organelles (AwMA), mitochondrial DNA (AmtDNA) or RNA (AmtRNA) are expressed in patients with systemic lupus erythematosus, an autoimmune disease often associated with APS. In this study, we detected AMA in patients with APS and associated their titers with clinical features of APS.

Methods: AwMA, AmtDNA and AmtRNA – IgG and IgM were detected in healthy controls (n=30) and APS patients (n=27) by direct ELISA. All participants agreed to participate to our Systemic Autoimmune Rheumatic Diseases Biobank and Data Base. Demographic and disease characteristic variables were collected according to the standard APS ACTION protocol. Vascular events were defined as arterial, venous or microangiopathic and «any vascular event» was defined as the combination of all types of vascular events Morbidities during pregnancy were defined as spontaneous abortions before the 10th week of pregnancy, miscarriages after the 10th week or premature birth due to eclampsia or preeclampsia before the 34th week and «any pregnancy morbidity» was defined as any combination of one or more items. Kruskall-Wallis and Wilcoxon tests were used to compare groups. Vascular events and morbidities during pregnancy were predicted with logistic regressions.

Results: AmtDNA-IgM and both AmtRNA IgG and IgM were significantly elevated in APS patients compared to controls.  AMA failed to discriminate primary APS (n=7) from secondary APS (n=20). AwMA-IgG were associated with positivity to lupus anticoagulant (p=0.01). While the AMA were not associated with morbidities during pregnancy, AwMA-IgM, AmtDNA-IgG and IgM and AmtRNA-IgM were all associated with reduced history of any thrombotic events (respectively p=0.0447, p=0.0414, p=0.0363 and p=0.0481). AmtDNA-IgM was also associated with reduced arterial vascular events (p=0.0463).

Conclusion: Our findings suggest that AMA are represented within the autoantibody repertoire in APS and that various mitochondrial antigens display different clinical associations in the disease.


ACR-ARP – 2019 Figure 1

Figure 1: Detection of anti-mitochondrial autoantibodies targeting whole mitochondria -AwMA-, mitochondrial DNA -AmtDNA- or RNA -AmtRNA- in healthy donors -n=30- and APS patients -n=27-


Table 1

Table 1: Clinical characteristics of APS patients

  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibodies-targeting-mitochondrial-antigens-are-associated-with-reduced-thrombotic-events-in-aps/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology